# PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

> **NCT06429696** · PHASE2 · RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** PD-L1 inhibitor combined with apatinib

## Key facts

- **NCT ID:** NCT06429696
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-14
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429696, "PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06429696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*